Gilead plans to halt free access to an HIV drug, worrying patient advocates
Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the end of January.
Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the end of January.
The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single physician to handle.
A new depression treatment developed by startup Neumora Therapeutics failed in a Phase 3 clinical trial — the company’s first late-stage readout.
The outgoing surgeon general will have to rely on Congress and the next administration to add warnings about cancer risks to alcohol labels.
Vincenza Conteduca discusses the RAPSON trial, which compares treatment sequencing of radium-223 and docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed on…
A new study led by researchers at the American Museum of Natural History presents the oldest known example in the fossil record of an evolutionary…
STAT Madness Application: the best innovations from research institutions in the United States STAT Madness identifies the top discoveries in biomedicine
Three issues to watch in global health in 2025: H5N1 bird flu, mpox, and U.S. influence on the global stage.
The alcohol industry relies on the myth of “responsible enjoyment” to downplay its products’ risks while spreading misinformation to stifle regulation.
The killing of UnitedHealthcare CEO Brian Thompson has sparked extraordinary public interest in the nation’s health insurance industry. Much of the outcry
Marty Makary and RFK Jr. are poised to make their marks on the FDA.